BVS — Bioventus Inc

Bioventus Inc (BVS) is a medical devices company listed on NASDAQ. It is led by Robert E. Claypoole, based in 4721 Emperor Boulevard, Durham, NC, United States, 27703, with about 930 employees. Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Latest reported BVS revenue for 2025-09-27 was $138.7M. Net income was $4.0M. Revenue was down 6.1% from 2025-06-28 to 2025-09-27. BVS currently screens at market cap $495.1M.

Use this BVS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BVS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BVS SEC filings page. Lician reads the product cache first so this HTML stays unique to Bioventus Inc even when a live quote feed is slow.